35 results on '"Bittenbring, Joerg"'
Search Results
2. KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
3. Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy
4. Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma
5. Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT
6. Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT
7. Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma
8. The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab
9. Hyperphosphorylation of autoantigenic targets of paraproteins is due to inactivation of PP2A
10. Hyperphosphorylation of autoantigenic targets of paraproteins is due to inactivation of PP2A
11. The Addition of Rituximab to Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (CHOP) Prolongs Overall Survival in Previously Untreated Mantle Cell Lymphoma: A Long Term Pooled Trials Analysis
12. The Addition of Rituximab to Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (CHOP) Prolongs Overall Survival in Previously Untreated Mantle Cell Lymphoma: A Long Term Pooled Trials Analysis
13. Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
14. Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
15. Safety and Efficacy of Idelalisib Treatment of Chronic Lymphocytic Leukemia (CLL) or Lymphoma Relapsing after Allogeneic Hematopoietic Cell Transplantation (alloHCT): A Survey By the EBMT Chronic Malignancies and Lymphoma Working Parties
16. Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial
17. Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
18. Salvage High-Dose Melphalane and Autologous Peripheral Blood Stem Cell Transplantation for Diffuse Large b-Cell Lymphoma Refractory to 2nd or 3rd Line Treatment
19. Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
20. the IKZF1-IRF4 Axis Regulates Macrophage Polarization and Macrophage-Mediated Anti-Tumor Immunity
21. Salvage High-Dose Melphalane and Autologous Peripheral Blood Stem Cell Transplantation for Diffuse Large b-Cell Lymphoma Refractory to 2nd or 3rd Line Treatment
22. Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial
23. the IKZF1-IRF4 Axis Regulates Macrophage Polarization and Macrophage-Mediated Anti-Tumor Immunity
24. Optimizing 25-OH-Vitamin D3 Serum Levels for Rituximab- and Obinutuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity
25. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT
26. Lenalidomide Enhances MOR202 Dependent Macrophage-Mediated Effector Functions Via the Vitamin D Pathway
27. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT
28. Lenalidomide Enhances MOR202 Dependent Macrophage-Mediated Effector Functions Via the Vitamin D Pathway
29. Optimizing 25-OH-Vitamin D3 Serum Levels for Rituximab- and Obinutuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity
30. Vitamin D-Dependent Induction of Cathelicidin in Human Macrophages Results in Cytotoxicity Against High Grade B-Cell Lymphoma
31. Vitamin D-Dependent Induction of Cathelicidin in Human Macrophages Results in Cytotoxicity Against High Grade B-Cell Lymphoma
32. 25-OH-Vitamin-D Deficiency Impairs Rituximab-Mediated Cellular Cytotoxicity and Is Associated With An Inferior Outcome Of Elderly DLBCL Patients Treated With Rituximab
33. 25-OH-Vitamin-D Deficiency Impairs Rituximab-Mediated Cellular Cytotoxicity and Is Associated With An Inferior Outcome Of Elderly DLBCL Patients Treated With Rituximab
34. Identification of New Minor Histocompatibility Antigens (mHags) in Patients with Chronic Graft Versus Host Disease (GvH) after Allogeneic Stem Cell Transplantation by SEREX.
35. Identification of New Minor Histocompatibility Antigens (mHags) in Patients with Chronic Graft Versus Host Disease (GvH) after Allogeneic Stem Cell Transplantation by SEREX.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.